Source comparison
Top Sermorelin Studies: Clinical Efficacy Comparison
Prakash 1997 (UVA) Double-blind RCT, 16 weeks 48 adults with GH deficiency IGF-1 change from baseline +14.2% vs placebo p=0.003 Established sermorelin's ability to raise IGF-1 in deficient adults. Gold standard efficacy trial Walker 2008 (aging males) Placebo-
This comparison does not assign a generated winner or score.
- Prakash 1997 (UVA)
- Double-blind RCT, 16 weeks
- 48 adults with GH deficiency
- IGF-1 change from baseline
- +14.2% vs placebo
- p=0.003
- Established sermorelin's ability to raise IGF-1 in deficient adults. Gold standard efficacy trial
- Walker 2008 (aging males)
- Placebo-controlled RCT, 24 weeks
- 62 men aged 55–75
- IGF-1 and GH pulsatility
- +19.7% IGF-1, improved pulse amplitude
- p=0.007 for IGF-1
- Showed sermorelin works in non-deficient aging adults but did NOT improve body composition
- Ghigo 1996 (Italy, multicenter)
- Dose-response RCT, 12 weeks
- 120 adults with GH deficiency
- Dose-response curve for IGF-1
- 1 mg optimal, 3 mg no added benefit
- p<0.001 vs placebo at 1 mg
- Defined the standard 1 mg nightly dose still used today
- Corpas 1993 (JCEM)
- Open-label safety trial, 18 months
- 87 adults with GH deficiency
- Adverse event rate
- 18% injection-site reactions, no serious AEs
- Not applicable (safety study)
- Longest safety data available. Established sermorelin's favorable tolerability profile
- Veldhuis 2004 (Germany)
- Crossover trial, 16 weeks
- 18 subjects with isolated GHD
- Pulsatile vs continuous infusion
- Pulsatile dosing superior for sustained response
- p=0.019
- Confirmed that bolus dosing mimics physiology better than continuous infusion